OJEMD  Vol.2 No.4 , November 2012
Inhibited 131I Uptake but Normal Release of Thyroid Hormone by Thyroid Gland in Response to TSH Administration in Subclinical Hypothyroidism
Author(s) Udaya M. Kabadi*
ABSTRACT
Background: Subclinical hypothyroidism is characterized by normal circulating thyroid hormone levels with super-normal TSH concentrations in absence of clinical manifestations. In majority of subjects, an etiologic factor is often identified. Moreover, therapy with levothyroxine normalizes serum TSH concentration while maintaining normal thyroid hormone concentrations. However, the exact pathophysiology of these thyroid hormone alterations is not well defined. Objective: Major steps in synthesis i.e. iodine uptake and the release of thyroid hormones in response to SC TSH administration were assessed in subjects with subclinical hypothyroidism. Methods: 10 men and 5 women with subclinical hypothyroidism, ages 42 - 76 years and 10 euthyroid men (39 - 70 years) participated. 24 hr 131Iodine thyroid uptake and serum T3, T4 and TSH concentrations were determined prior to and after SC administration of recombinant human TSH, 0.9 mg for two consecutive days. Comparisons were conducted for 24 hour uptake values as well as serum T3, T4 and TSH levels obtained prior to and after TSH administration. Results: In subjects with subclinical hypothyroidism 24 hour 131I thyroidal uptakes were normal (10% - 30%). However, the mean value was significantly lower, (p < 0.05) as compared to euthyroid volunteers. 24 hr uptakes rose following TSH administration in both groups. However, the rise was significant (p < 0.01) only in normal subjects. Furthermore, both the mean absolute uptake and the mean % rise following TSH administration were markedly significantly lower in subjects with subclinical hypothyroidism in comparison to normal subjects. Serum T3 and T4 concentrations in subjects with subclinical hypothyroidism were not significantly different in comparison to normal subjects. Serum TSH concentrations were supernormal and therefore were significantly higher in subjects with subclinical hypothyroidism in comparison to normal subjects and rose markedly in both groups following TSH administration with no significant difference among groups. Serum T4 and T3 rose significantly from PreTSH levels in both groups (p < 0.05). However, the rises were not significantly different between groups. Conclusion: In subjects with subclinical hypothyroidism secondary to Hashimoto’s thyroiditis, 24 hour 131I Thyroid uptake is inhibited prior to as well as following SC TSH administration in comparison to normal subjects with maintenance of normal hormone release.

Cite this paper
U. M. Kabadi, "Inhibited 131I Uptake but Normal Release of Thyroid Hormone by Thyroid Gland in Response to TSH Administration in Subclinical Hypothyroidism," Open Journal of Endocrine and Metabolic Diseases, Vol. 2 No. 4, 2012, pp. 98-101. doi: 10.4236/ojemd.2012.24015.
References
[1]   W. M. Tunbridge, D. C. Evered, R. Hall, D. Appleton, M. Brewis, F. Clark, J. G. Evans, E. Young, T. Bird and P. A. Smith, “The Spectrum of Thyroid Disease in a Community: The Whickham Survey,” Journal of Clinical Endocrinology, Vol. 7, No. 6, 1977, pp. 481-493. doi:10.1111/j.1365-2265.1977.tb01340.x

[2]   A. Gordin and B. A. Lamberg, “Spontaneous Hypothyroidism in Symptomless Autoimmune Thyroiditis. A Long-Term Follow-Up Study,” Journal of Clinical Endocrinology, Vol. 15, No. 6, 1981, pp. 537-543.

[3]   U. M. Kabadi, “Subclinical Hypothyroidism: Natural Course of the Syndrome during a Prolonged Follow-Up Study,” Archives of Internal Medicine, Vol. 153, No. 8, 1993, pp. 958-961.

[4]   M. P. J. Vanderpump, W. M. G. Tunbridge, J. M. French, et al., “The Incidence of Thyroid Disease in the Community. A Twenty Year Follow-Up of the Whickham Survey,” Clinical Endocrinology, Vol. 43, No. 1, 1995, pp. 55-68.

[5]   U. M. Kabadi and R. Cech, “Normal Thyroxine and Elevated Thyrotropin Concentrations: Evolving Hypothyroidism or Persistent Euthyroidism with Reset Thyrostat,” Journal of Endocrinological Investigation, Vol. 20, No. 6, 1997, pp. 319-326.

[6]   N. Clarke and U. M. Kabadi, “Optimizing Treatment of Hypothyroidism,” Treatments in Endocrinology, Vol. 3, No. 4, 2004, pp. 217-221. doi:10.2165/00024677-200403040-00003

[7]   U. M. Kabadi, “Optimal Daily L-thyroxine Dosage in Primary Hypothyroidism: The Role of Pathogenetic Causes,” Iowa Medicine, Vol. 84, No. 12, 1994, pp. 535-537.

[8]   M. Helfand, “Preventive Services Task Force. Screening for Subclinical Thyroid Dysfunction in Nonpregnant Adults: A Summary of the Evidence for the US Preventive Services Task Force,” Annals of Internal Medicine, Vol. 140, No. 2, 2004, pp. 128-141.

[9]   M. I. Surks, E. Ortiz, G. H. Daniels, C. T. Sawin, N. F. Col, R. H. Cobin, J. A. Franklyn, J. M. Hershman, K. D Burman, M. A. Denke, C. Gorman, R. S. Cooper and N. J. Weissman, “Subclinical Thyroid Disease: Scientific Review and Guidelines for Diagnosis and Management,” The Journal of American Medical Association, Vol. 291, No. 2, 2004, pp. 228-238. doi:10.1001/jama.291.2.228

[10]   N. F. Col, M. I. Surks and G. H. Daniels, “Subclinical Thyroid Disease: Clinical Applications,” The Journal of American Medical Association, Vol. 291, No. 2, 2004, pp. 239-243. doi:10.1001/jama.291.2.239

[11]   J. G. Hollowell, N. W. Staehling, W. D. Flanders, W. H. Hannon, E. W. Gunter, C. A. Spencer and L. E. Braverman, “Serum TSH T4, and Thyroid Antibodies in the United States Population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III),” Journal of Clinical Endocrinology & Metabolism, Vol. 87, No. 2, 2002, pp. 489-499. doi:10.1210/jc.87.2.489

[12]   J. Karmisholt, S. Andersen and P. Laurberg, “Variation in Thyroid Function in Subclinical Hypothyroidism: Importance of Clinical Follow-Up and Therapy,” European Journal of Endocrinology, Vol. 164, No. 3, 2011, pp. 317-323. doi:10.1530/EJE-10-1021

[13]   M. J. Boomsma, H. P. Bijl and J. A. Langendijk, “Radiation-Induced Hypothyroidism in Head and Neck Cancer Patients: A Systematic Review,” Radiotherapy & Oncology, Vol. 99, No. 1, 2011, pp. 1-5. doi:10.1016/j.radonc.2011.03.002

[14]   B. Gopinath, J. J. Wang, A. Kifley, J. R. Wall, C. J. Eastman, S. R. Leeder and P. Mitchell, “Five-Year Incidence and Progression of Thyroid Dysfunction in an Older Population,” European Journal of Internal Medicine, Vol. 40, No. 9, 2010, pp. 642-649. doi:10.1111/j.1445-5994.2009.02156.x

[15]   D. D. Jones, K. E. May and S. A. Geraci, “Subclinical Thyroid Disease,” American Journal of Medicine, Vol. 123, No. 6, 2010, pp. 502-504. doi:10.1016/j.amjmed.2009.12.023

[16]   G. Ceresini, S. Morganti, M. Maggio, E. Usberti, I. Fiorino, A. Artoni, G. Teresi, S. Belli, V. Ridolfi, G. Valenti and G. P. Ceda, “Subclinical Thyroid Disease in Elderly Subjects,” Acta BioMedica, Vol. 81, No. S1, pp. 31-36.

[17]   D. S. Cooper, R. Halpern, L. C. Wood, A. A. Levin and E. C. Ridgway, “L-Thyroxine Therapy in Subclinical Hypothyroidism. A Double-Blind, Placebo-Controlled Trial,” Annals of Internal Medicine, Vol. 101, No. 1, 1984, pp. 18-24.

[18]   E. Nystr?m, K. Caidahl, G. Fager, C. Wikkels?, P. A. Lundberg and G. Lindstedt, “A Double-Blind Cross-Over 12-Month Study of L-Thyroxine Treatment of Women with ‘Subclinical’ Hypothyroidism,” Journal of Clinical Endocrinology, Vol. 29, No. 1, 1988, pp. 63-75. doi:10.1111/j.1365-2265.1988.tb00250.x

[19]   E. C. Ridgway, D. S. Cooper, H. Walker, D. Rodbard and F. Maloof, “Peripheral Responses to Thyroid Hormone before and after L-Thyroxine Therapy in Patients with Subclinical Hypothyroidism,” Journal of Clinical Endocrinology & Metabolism, Vol. 53, No. 6, 1981, pp. 1238-1242. doi:10.1210/jcem-53-6-1238

[20]   J. T. Dunn and A. D. Dunn, “Update on Intrathyroidal Iodine Metabolism,” Thyroid, Vol. 11, No. 5, 2001, pp. 407-414. doi:10.1089/105072501300176363

[21]   W. E. Winter and M. R. Signorino, “Review: Molecular Thyroidology,” Annals of Clinical and Laboratory Science, Vol. 31, No. 3, 2001, pp. 221-244.

[22]   B. Rapoport, “Pathophysiology of Hashimoto’s Thyroiditis and Hypothyroidism,” Annual Review of Medicine, Vol. 42, 1991, pp. 91-96. doi:10.1146/annurev.me.42.020191.000515

[23]   M. Nakhjavani and H. Gharib, “Diffuse Nontoxic and Multinodular Goiter,” Current Therapy in Endocrinology and Metabolism, Vol. 6, 1997, pp. 109-112.

[24]   M. Derwahl and H. Studer, “Nodular Goiter and Goiter Nodules: Where Iodine Deficiency Falls Short of Explaining the Facts,” Experimental and Clinical Endocrinology & Diabetes, Vol. 109, No. 5, 2001, pp. 250-260. doi:10.1055/s-2001-16344

[25]   W. Reinhardt, M. Luster, K. H. Rudorff, C. Heckmann, S. Petrasch, S. Lederbogen, R. Haase, B. Saller, C. Reiners, D. Reinwein and K. Mann, “Effect of Small Doses of Iodine on Thyroid Function in Patients with Hashimoto's Thyroiditis Residing in an Area of Mild Iodine Deficiency,” European Journal of Endocrinology, Vol. 139, No. 1, 1998, pp. 23-28. doi:10.1530/eje.0.1390023

[26]   J. H. Lazarus, “The Effects of Lithium Therapy on Thyroid and Thyrotropin-Releasing Hormone,” Thyroid, Vol. 8, No. 10, 1998, pp. 909-913. doi:10.1089/thy.1998.8.909

[27]   G. Barbesino, “Drugs Affecting Thyroid Function,” Thyroid, Vol. 20, No. 7, 2010, pp. 763-770. doi:10.1111/j.1365-2265.1991.tb00314.x

[28]   C. C. Chow, D. I. Phillips, J. H. Lazarus and A. B. Parkes, “Effect of Low Dose Iodide Supplementation on Thyroid Function in Potentially Susceptible Subjects: Are Dietary Iodide Levels in Britain Acceptable?” Journal of Clinical Endocrinology, Vol. 34, No. 5, 1991, pp. 413-416. doi:10.1111/j.1365-2265.1991.tb00314.x

[29]   Z. Sang, P. P. Wang, Z. Yao, J. Shen, B. Halfyard, et al., “Exploration of The Safer Upper Level of Iodine Intake in Euthyroid Chinese Adults: A Randomized Double Blind Trial,” The American Journal of Clinic Nutrition, Vol. 95, No. 2, 2012, pp. 367-373.

 
 
Top